Hannes Leupe, Elin Pauwels, Timon Vandamme, Bliede Van den Broeck, Willem Lybaert, Jeroen Dekervel, Filip Van Herpe, Joris Jaekers, Frederik Cleeren, Johannes Hofland, Adrienne Brouwers, Michel Koole, Guy Bormans, Eric Van Cutsem, Karen Geboes, Annouschka Laenen, Chris Verslype, Sigrid Stroobants, Christophe M. Deroose
{"title":"使用[18F]AlF-NOTA-奥曲肽 PET/CT 代替[68Ga]Ga-DOTA-SSA PET/CT 的临床影响：一项多中心前瞻性试验的次要终点分析。","authors":"Hannes Leupe, Elin Pauwels, Timon Vandamme, Bliede Van den Broeck, Willem Lybaert, Jeroen Dekervel, Filip Van Herpe, Joris Jaekers, Frederik Cleeren, Johannes Hofland, Adrienne Brouwers, Michel Koole, Guy Bormans, Eric Van Cutsem, Karen Geboes, Annouschka Laenen, Chris Verslype, Sigrid Stroobants, Christophe M. Deroose","doi":"10.1111/jne.13420","DOIUrl":null,"url":null,"abstract":"<p>[<sup>18</sup>F]AlF-NOTA-octreotide ([<sup>18</sup>F]AlF-OC) is a promising alternative for [<sup>68</sup>Ga]Ga-DOTA-somatostatin analogs (SSAs) in positron emission tomography (PET) imaging of the somatostatin receptor (SSTR). Our aim is to assess changes in TNM staging and differences in patient management between [<sup>18</sup>F]AlF-OC PET/CT and [<sup>68</sup>Ga]Ga-DOTA-SSA PET/CT in the work-up of neuroendocrine tumor (NET) patients. Patients who underwent both [<sup>18</sup>F]AlF-OC and [<sup>68</sup>Ga]Ga-DOTA-TATE or [<sup>68</sup>Ga]Ga-DOTA-NOC PET/CT in our multicenter study (Pauwels et al., <i>J Nucl Med</i>.2023;63:632–638) with a NET were included for analysis. TNM staging was determined and compared for both tracers. For each patient, the blinded [<sup>68</sup>Ga]Ga-DOTA-SSA or [<sup>18</sup>F]AlF-OC PET/CT images were presented in random order at a multidisciplinary team board. The images were presented together with clinical information and compared with previous SSTR and [<sup>18</sup>F]FDG PET/CT imaging. After a consensus decision for patient management was recorded, the board was presented with the PET/CT images from the other SSTR tracer and a decision was made for the second tracer. Differences in management were classified as major if it entailed an intermodality change and minor if it led to an intramodality change. Compared with [<sup>68</sup>Ga]Ga-DOTA-SSA, the use of [<sup>18</sup>F]AlF-OC led to a change in 16/75 patients: TNM staging changes in 10/75 patients (13.3%; downstaging in 3/10, upstaging in 7/10) and differences in clinical management were seen in 10/75 patients (13.3%), leading to a major difference in 7/10 cases and a minor change in 3/10 cases. All 10 cases with a difference in patient management between both PET tracers were caused by additional lesion detection by [<sup>18</sup>F]AlF-OC. The use of [<sup>18</sup>F]AlF-OC did not impact TNM staging or clinical management in the large majority of the patients (86.7%), further validating the potential for routine clinical use of [<sup>18</sup>F]AlF-OC PET/CT as an alternative for [<sup>68</sup>Ga]Ga-DOTA-SSA PET/CT. The trial is registered under ClinicalTrials.gov identifier NCT04552847 and EudraCT 2020–000549-15.</p>","PeriodicalId":16535,"journal":{"name":"Journal of Neuroendocrinology","volume":"36 8","pages":""},"PeriodicalIF":3.3000,"publicationDate":"2024-06-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Clinical impact of using [18F]AlF-NOTA-octreotide PET/CT instead of [68Ga]Ga-DOTA-SSA PET/CT: Secondary endpoint analysis of a multicenter, prospective trial\",\"authors\":\"Hannes Leupe, Elin Pauwels, Timon Vandamme, Bliede Van den Broeck, Willem Lybaert, Jeroen Dekervel, Filip Van Herpe, Joris Jaekers, Frederik Cleeren, Johannes Hofland, Adrienne Brouwers, Michel Koole, Guy Bormans, Eric Van Cutsem, Karen Geboes, Annouschka Laenen, Chris Verslype, Sigrid Stroobants, Christophe M. Deroose\",\"doi\":\"10.1111/jne.13420\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p>[<sup>18</sup>F]AlF-NOTA-octreotide ([<sup>18</sup>F]AlF-OC) is a promising alternative for [<sup>68</sup>Ga]Ga-DOTA-somatostatin analogs (SSAs) in positron emission tomography (PET) imaging of the somatostatin receptor (SSTR). Our aim is to assess changes in TNM staging and differences in patient management between [<sup>18</sup>F]AlF-OC PET/CT and [<sup>68</sup>Ga]Ga-DOTA-SSA PET/CT in the work-up of neuroendocrine tumor (NET) patients. Patients who underwent both [<sup>18</sup>F]AlF-OC and [<sup>68</sup>Ga]Ga-DOTA-TATE or [<sup>68</sup>Ga]Ga-DOTA-NOC PET/CT in our multicenter study (Pauwels et al., <i>J Nucl Med</i>.2023;63:632–638) with a NET were included for analysis. TNM staging was determined and compared for both tracers. For each patient, the blinded [<sup>68</sup>Ga]Ga-DOTA-SSA or [<sup>18</sup>F]AlF-OC PET/CT images were presented in random order at a multidisciplinary team board. The images were presented together with clinical information and compared with previous SSTR and [<sup>18</sup>F]FDG PET/CT imaging. After a consensus decision for patient management was recorded, the board was presented with the PET/CT images from the other SSTR tracer and a decision was made for the second tracer. Differences in management were classified as major if it entailed an intermodality change and minor if it led to an intramodality change. Compared with [<sup>68</sup>Ga]Ga-DOTA-SSA, the use of [<sup>18</sup>F]AlF-OC led to a change in 16/75 patients: TNM staging changes in 10/75 patients (13.3%; downstaging in 3/10, upstaging in 7/10) and differences in clinical management were seen in 10/75 patients (13.3%), leading to a major difference in 7/10 cases and a minor change in 3/10 cases. All 10 cases with a difference in patient management between both PET tracers were caused by additional lesion detection by [<sup>18</sup>F]AlF-OC. The use of [<sup>18</sup>F]AlF-OC did not impact TNM staging or clinical management in the large majority of the patients (86.7%), further validating the potential for routine clinical use of [<sup>18</sup>F]AlF-OC PET/CT as an alternative for [<sup>68</sup>Ga]Ga-DOTA-SSA PET/CT. The trial is registered under ClinicalTrials.gov identifier NCT04552847 and EudraCT 2020–000549-15.</p>\",\"PeriodicalId\":16535,\"journal\":{\"name\":\"Journal of Neuroendocrinology\",\"volume\":\"36 8\",\"pages\":\"\"},\"PeriodicalIF\":3.3000,\"publicationDate\":\"2024-06-04\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Neuroendocrinology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://onlinelibrary.wiley.com/doi/10.1111/jne.13420\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"ENDOCRINOLOGY & METABOLISM\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Neuroendocrinology","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1111/jne.13420","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}
Clinical impact of using [18F]AlF-NOTA-octreotide PET/CT instead of [68Ga]Ga-DOTA-SSA PET/CT: Secondary endpoint analysis of a multicenter, prospective trial
[18F]AlF-NOTA-octreotide ([18F]AlF-OC) is a promising alternative for [68Ga]Ga-DOTA-somatostatin analogs (SSAs) in positron emission tomography (PET) imaging of the somatostatin receptor (SSTR). Our aim is to assess changes in TNM staging and differences in patient management between [18F]AlF-OC PET/CT and [68Ga]Ga-DOTA-SSA PET/CT in the work-up of neuroendocrine tumor (NET) patients. Patients who underwent both [18F]AlF-OC and [68Ga]Ga-DOTA-TATE or [68Ga]Ga-DOTA-NOC PET/CT in our multicenter study (Pauwels et al., J Nucl Med.2023;63:632–638) with a NET were included for analysis. TNM staging was determined and compared for both tracers. For each patient, the blinded [68Ga]Ga-DOTA-SSA or [18F]AlF-OC PET/CT images were presented in random order at a multidisciplinary team board. The images were presented together with clinical information and compared with previous SSTR and [18F]FDG PET/CT imaging. After a consensus decision for patient management was recorded, the board was presented with the PET/CT images from the other SSTR tracer and a decision was made for the second tracer. Differences in management were classified as major if it entailed an intermodality change and minor if it led to an intramodality change. Compared with [68Ga]Ga-DOTA-SSA, the use of [18F]AlF-OC led to a change in 16/75 patients: TNM staging changes in 10/75 patients (13.3%; downstaging in 3/10, upstaging in 7/10) and differences in clinical management were seen in 10/75 patients (13.3%), leading to a major difference in 7/10 cases and a minor change in 3/10 cases. All 10 cases with a difference in patient management between both PET tracers were caused by additional lesion detection by [18F]AlF-OC. The use of [18F]AlF-OC did not impact TNM staging or clinical management in the large majority of the patients (86.7%), further validating the potential for routine clinical use of [18F]AlF-OC PET/CT as an alternative for [68Ga]Ga-DOTA-SSA PET/CT. The trial is registered under ClinicalTrials.gov identifier NCT04552847 and EudraCT 2020–000549-15.
期刊介绍：
Journal of Neuroendocrinology provides the principal international focus for the newest ideas in classical neuroendocrinology and its expanding interface with the regulation of behavioural, cognitive, developmental, degenerative and metabolic processes. Through the rapid publication of original manuscripts and provocative review articles, it provides essential reading for basic scientists and clinicians researching in this rapidly expanding field.
In determining content, the primary considerations are excellence, relevance and novelty. While Journal of Neuroendocrinology reflects the broad scientific and clinical interests of the BSN membership, the editorial team, led by Professor Julian Mercer, ensures that the journal’s ethos, authorship, content and purpose are those expected of a leading international publication.
![Clinical impact of using [18F]AlF-NOTA-octreotide PET/CT instead of [68Ga]Ga-DOTA-SSA PET/CT: Secondary endpoint analysis of a multicenter, prospective trial](https://img.booksci.cn/booksciimg/2024-6/98291511261753106420.jpg)
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
